Novartis Reports Five-Year MONALEESA-3 Data for Kisqali in HR-Positive Breast Cancer

Novartis today presented five-year overall survival data from the Phase 3 MONALEESA-3 trial evaluating Kisqali (ribociclib) plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer. The data showed a significant improvement in overall survival with Kisqali, with a median overall survival of 53.7 months compared to 41.5 months in the placebo arm.